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multidrug-resistant gram-negative
pathogens, and enhanced measures
are needed to prevent spread of these
organisms. A greater understanding of
the modes of spread and acquisition of
these organisms is essential for effec-
tive control of this problem. We have
reported just 1 case of infection with
an almost completely resistant gram-
negative organism. This case expands
the known geographic spread of
organisms with this resistance prob-
lem. This case also underscores the
importance of studying the epidemiol-
ogy of antimicrobial drug resistance
in gram-negative organisms in the
rural setting as well as in large metro-
politan centers. Dissemination of
knowledge regarding appropriate
antimicrobial drug susceptibility test-
ing for resistant organisms is also
needed.
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Severe Pneumonia
and Human
Bocavirus in Adult
To the Editor: The newly identi-
fied human bocavirus (hBoV), a
member of the Parvovirus family, is
suspected to infect the cells of the res-
piratory tract and thus may be an etio-
logic agent of respiratory disease in
humans (1). Although Koch postu-
lates have not been fulfilled for HboV,
it appears likely to cause a substantial
number of respiratory tract infections,
at least in children (2,3). We describe
a case of severe atypical pneumonia
associated with hBoV DNA in a bron-
choalveolar lavage (BAL) sample
from an adult.
The patient was a 28-year-old
Caucasian woman with an angioim-
munoblastic T–non-Hodgkin lym-
phoma (NHL) that changed into a
highly malignant blastic B-cell lym-
phoma (T-cell–rich B-NHL state I
with 70% CD20+ cells, initial stage
IIIB). The patient was previously
treated with vincristine and pred-
nisone, followed by chemotherapy
according to the R-CHOEP-14 proto-
col (3 cycles) (November 2003
through January 2004). From January
through February 2004, chemothera-
py was combined with antimicrobial
drug therapy according to the R-
DHAP protocol (which includes dex-
amethasone, the chemotherapy drugs
cytarabine and cisplatin, and the mon-
oclonal antibody drug rituximab) for
persisting symptoms from the B-cell
lymphoma. This regimen was fol-
lowed by a therapy switch to alem-
tuzumab with ifosfamid, carboplatin,
and etoposide (March 2004), which
led to a therapy-induced leukopenia,
thrombocytopenia, and high fever
>40°C by the end of March and the
beginning of April 2004. In May
2004, a second round of alemtuzumab
with ifosfamid, carboplatin, and
etoposide chemotherapy was initiated.
In June 2004, a therapy-induced
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hemorrhagic cystitis occurred. During
July 2004, the patient had ongoing
high fever and aplasia of bone marrow
with unclear etiology. On July 22,
hospital treatment was initiated; it
consisted of antimicrobial drug treat-
ment with ceftriaxone (1,000 mg once
daily) and gentamicin (320 mg once
daily), and antimycotic therapy was
started with caspofungin (50 mg once
daily).
Since cytomegalovirus (CMV)
infection was suspected, ganciclovir
(250 mg twice daily) was adminis-
tered IV for 2 weeks. Although the
patient reported an ongoing cough
and pneumonialike symptoms, a
severe atypical pneumonia that was
refractive to antibacterial and antimy-
cotic treatment was diagnosed for the
first time during this hospital treat-
ment. Computed tomography scan
showed bilateral atypical reticulon-
odular infiltrations predominant in the
lower zones of the lungs (Figure).
The BAL obtained during exacer-
bation of the pulmonary symptoms
was tested for Mycobacterium tuber-
culosis, Chlamydia pneumoniae,
Pneumocystis jirovecii, Aspergillus
sp., Candida sp., Cryptococcus neo-
formans, CMV, Epstein-Barr virus,
hepatitis B virus, hepatitis C virus,
HIV, herpes simplex virus, and vari-
cella-zoster virus by PCR and culture
cultivation. Results were negative,
except for a temporarily weak reactiv-
ity for Aspergillus antigen in serum
and for CMV DNA in peripheral
blood lymphocytes, which was posi-
tive before and became negative after
ganciclovir therapy. An archived por-
tion of the BAL was assayed retro-
spectively by PCR/reverse transcrip-
tase–PCR for human bocavirus, respi-
ratory syncytial virus, human coron-
aviruses including severe acute respi-
ratory syndrome–associated coron-
avirus, influenza virus, and human
metapneumovirus (hMPV). The only
positive result was obtained for
human bocavirus, which was con-
firmed by sequence analysis of the
PCR product.
Within a few days, the patient’s
symptoms decreased, and she was dis-
charged from hospital on day 41,
despite ongoing bone marrow aplasia
with antimicrobial and antimycotic
prophylaxis, including trimethoprim/
sulfamethoxazole (160 mg/800 mg
once daily) and (voriconazole 200 mg
twice daily). Clinical observations led
to the primary assumption that the
fever, cough, and pulmonary symp-
toms were likely caused by the
postchemotherapeutic extended bone
marrow aplasia and CMV infection
accompanied by an unclear bacterial
but fungus-typical infection.
Retrospectively, however, human
bocavirus DNA in the archived BAL
strongly suggests that pulmonary
symptoms were caused by this agent
rather than by a yet unknown bacteri-
al or fungal infection. Thus, in the
clinical episode described here, the
likely causative agent responsible for
the severe pneumonia was the recent-
ly described bocavirus.
Respiratory viruses such as respi-
ratory syncytial virus, hMPV, and
hBoV seem to be the most prevalent
etiologic agents of acute lower respi-
ratory tract infection in children.
Recently, evidence of human
bocavirus infection was reported for
3.1% to 5.7% of children <3 years of
age (1–3). Previously, only limited
data on adults, including immuno-
compromised patients, were avail-
able, but the case we describe sup-
ports the hypothesis proposed for
other newly identified respiratory
viruses, namely, that these pathogens
also contribute to severe infections in
adult patients at high risk. For exam-
ple, hMPV was found in 3% of stem-
cell transplant recipients who under-
went BAL because of lower respirato-
ry tract infection (4). In those high-
risk patients, hMPV also induced fatal
infections (4). This finding led to the
conclusion that a “new” virus that
induces the identical clinical symp-
toms, like the human bocavirus, may
also contribute to severe respiratory
infections. In summary, this first
report of a respiratory tract infection
with hBoV in an adult immunocom-
promised patient strongly supports the
assumption that hBoV is an emerging
pathogen that requires our attention,
even for adult patients (1–3).
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Leishmaniasis in
Ancient Egypt and
Upper Nubia
To the Editor: Leishmaniasis is a
disease caused by parasites of the
genus Leishmania. The infection is
transmitted to humans through the
bites of female sandflies and mani-
fests mainly in 3 forms: visceral, cuta-
neous, and mucocutaneous. Visceral
leishmaniasis or kala-azar, the often
fatal form of the disease, is caused by
species of the Leishmania donovani
complex. These parasites were
responsible for severe recent out-
breaks in Sudan and other countries
and are thought to originate in East
Africa (1–4).
In this report, we describe the suc-
cessful amplification of L. donovani
DNA in ancient Egyptian and
Christian Nubian mummies dating
back 4,000 years. Besides the first
proof for visceral leishmaniasis in
paleopathology, we provide evidence
that leishmaniasis was present in
Nubia in the early Christian period
and that the organism also infected
ancient Egyptians, probably because
of close trading contacts to Nubia,
during the Middle Kingdom. We ana-
lyzed 91 bone tissue samples from
ancient Egyptian mummies and skele-
tons and 70 bone marrow samples
from naturally mummified human
remains from Upper Nubia. The
Egyptian material derived from the
Pre- to Early Dynastic site of Abydos
(n = 7; 3500–2800 BC), a Middle
Kingdom tomb in Thebes West (42;
2050–1650 BC), and different tomb
complexes in Thebes West, which
were built and used between the
Middle and New Kingdom until the
Late Period (42; c. 2050–500 BC). The
Nubian samples were taken before the
flooding caused by the Aswan Dam
from 2 early Christian burial sites at
Kulubnarti, between the second and
third cataracts of the Nile River in
northern Sudan. One site was on an
island in the Nile and dated from 550
to 750 AD. The other was on the west-
ern bank of the Nile and was in use
from c.750 to 1500 AD. All samples
were tested for Leishmania spp. DNA
and further characterized by direct
sequencing.
In 4 of the 91 Egyptian and 9 of the
70 Nubian samples, a 120-bp frag-
ment of a conserved region of the
minicircle molecule of kinetoplastid
mitochondrial DNA of the parasite
(5,6) could be successfully amplified
and, with the first primer pair, unam-
biguously related to L. donovani
species after sequencing (Figure). The
positive samples from ancient Egypt
exclusively originated from the
Middle Kingdom tomb, while no
molecular evidence for ancient
Leishmania DNA was found in the
Pre- to Early Dynastic and the New
Kingdom to Late Period specimens.
In the Middle Kingdom, the
Egyptians extended trade relation-
ships and military expeditions to
Nubia, the modern Sudan, with partic-
ular interest in the gold resources of
the country and in obtaining slaves to
serve as servants or soldiers in the
pharaoh’s army. Today, the Sudan is
one of the highly endemic countries
for visceral leishmaniasis or kala-
azar, which is thought to have origi-
nated in East Africa and later spread
to the Indian subcontinent and the
New World (4). Therefore, the high
incidence of Leishmania DNA in the
Middle Kingdom samples (4 [9.5%]
of 42) and the lack of findings in ear-
lier or later time periods, may indicate
that leishmaniasis was introduced into
Egypt at this time. Leishmaniasis did
not likely become endemic in the
Egyptian Nile Valley because the dis-
ease is closely linked to its vector, the
phlebotomine sandfly, and the distri-
bution of Acacia-Balanites woodland
(7). That ancient Egyptians became
infected because of close trade con-
tacts and associated travel with Nubia
during the Middle Kingdom seems
more plausible. The high frequency of
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